InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
6
T+90 hit rate
60%
T+90 mean return
+9.2%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by PYOTT DAVID E I, Director. Insider active across 2 companies, notably Biomarin Pharmaceutical INC. Cumulatively, 18 reports have been recorded. Breakdown: 0 buy · 6 sells. Total volume traded: €3m. Activity tracked since 25 May 2021. The latest transaction was filed on 1 June 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations18 total
3,830 shares0Common StockSEC:0001178670-26-000048:0
921 shares@ US$297.710.0006% mcap4.6% of flowCommon StockSEC:0001178670-26-000048:1
1,175 shares@ US$298.910.0008% mcap5.9% of flowCommon StockSEC:0001178670-26-000048:2
1,222 shares@ US$299.870.0008% mcap6.2% of flowCommon StockSEC:0001178670-26-000048:3
495 shares@ US$300.720.0003% mcap2.5% of flowCommon StockSEC:0001178670-26-000048:4
17 shares@ US$302.650.0000% mcap0.1% of flowCommon StockSEC:0001178670-26-000048:5
671 shares0Common StockSEC:0001178670-26-000039:0
775 shares0Common StockSEC:0001735276-25-000063:0
7,440 shares@ US$299.0040.2% of flowCommon StockSEC:0001735276-25-000040:1
7,440 shares@ US$88.9512.0% of flowCommon StockSEC:0001735276-25-000040:0
17,560 shares@ US$88.9528.5% of flowCommon StockSEC:0001735276-24-000070:0
4,720 shares0Common StockSEC:0001048477-24-000110:0
4,190 shares0Common StockSEC:0001209191-23-031977:0
136 shares0Common StockSEC:0001735276-23-000018:0
4,980 shares0Common StockSEC:0001567619-22-011800:0
5,120 shares0Common StockSEC:0001567619-21-011320:0
5,120 shares0Common StockSEC:0001567619-21-011320
2,100 sharesCommon StockSEC:0001140361-16-046894:0
18 of 18 declarations
About PYOTT DAVID E I
David E I Pyott is a Board Member at BioMarin Pharmaceutical Inc. He plays a key role in the governance of the company and strategic decision-making. His expertise in the pharmaceutical sector is valuable to the board.
